Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
How I missed this one I don't know but watching the interview with Neil Crabb it looks very good indeed.
Frontier IP Group PLC’s (LON:FIPP) has exposure to Covid-19 via portfolio company The Vaccine Group who is working on formulations for animals to prevent coronaviruses from infecting humans again. They also have a stake in Exscientia who are a world leader in AI-driven drug discovery, they are to progress compounds that could rapidly become viable drugs for treating COVID-19 in a joint initiative with Diamond Light Source and Calibr, a division of Scripps Research (USA). This news seems to have been missed by the market and the drug is already FDA approved and clinical trials have begun funded by the Bill Gates foundation.
https://www.diamond.ac.uk/Home/News/LatestNews/2020/31-03-2020.html
https://www.youtube.com/watch?time_continue=493&v=_2_q8RWH4sU&feature=emb_logo
Huge RNS today!! Big things coming in the fight against Coronavirus
SNG human clinical trials of thier Inhaler phase 2 started today covid19
Article adjusted short term target £1 in relation of undervalued shareholding. See Baldyetis link. Seems worth a long term hold too. Excellent chances of growth here
Already invested in great companies and will continue too grow. Strong Buy IMO
Quite a scattering of recent RNS's from FIPP, in recent weeks.
A likely riser going forward, is my feeling.
This share looks undervalued to me. Been perusing its fundamentals and I like what I see so far...
https://www.investorschronicle.co.uk/comment/2020/02/17/aim-traded-shares-that-hit-the-target/
Hi there all, well probably just Troajan ( I watch you on the WRES board and I'm invested there as well). I've had a look at this stock and recently opted to buy in at SP 67. I'm thinking as a long term investment this could work out really well as having the kind of relationships with the universities and access to the ip's spun out can only be a good thing. Latest interview from Proactive shows they are pretty bullish and that aspects of their portfolio and starting to mature. So my question is this...I do think this is a solid buy but where could we expect the sp to reach in say five years? It's a very quiet board so I'm thinking FIPP is just slipping under the radar for most people. Anyone???
Recent news must be positively impacting.
https://www.investegate.co.uk/frontier-ip-group--fipp-/rns/amprologix-to-develop-new-antibiotics-with-ingenza/201809200700172951B/
hmm nt trade only cant buy buiscuits
Ouch... it's crazy quite in here! ...anyway... just been looking though reports, fundamentals, even the technical stuff and all looks pretty good, the next set of results are in October, but thinking of topping up now if not very soon, Very happy to still go long
This must be one of the most steady AIM shares on the Market and has also seen a 400% growth in the SP over the last 2 years. Still worth a punt on any dips.
Good luck to all for what should be a fantastic 2018 as some of the portfolio organizations hit market potential.
The Capital Markets day should be a great opportunity to get the latest picture on some of the products in development. I am particularly keen to see if Nandi Proteins is near to market acceptance - that'll be a game changer !
No doubt many of the herd who posted on Monday are now embarrassed about how they failed to notice that FIPP only hold 5% of Exscientia. It was still a good RNS and is further evidence of the quality of FIPP's intellectual property. This company is steadily growing and is managed well and even those who got spiked will eventually see the the SP recover. Those buying in whilst the SP is still below 40p should do well.
Higher than it is now
So what do you think today's RNS does to the value of Exscientia relative to FIPP market value?
Err hello, £10m is equal to the entire m.cap. of Frontier!
10m share max - assuming the company is going to distribute its profits to its shareholders - which is unlikely given the nature of their business - they will need the funds for further research/investments.